These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38534102)

  • 1. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Cossu MV; D'Avolio A; Gervasoni C; Giacomelli A; Cattaneo D; Moschese D
    Antimicrob Agents Chemother; 2024 May; 68(5):e0017524. PubMed ID: 38534104
    [No Abstract]   [Full Text] [Related]  

  • 3. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
    AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
    Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
    Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
    AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabotegravir and rilpivirine for the treatment of HIV.
    Rial-Crestelo D; Pinto-Martínez A; Pulido F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
    [No Abstract]   [Full Text] [Related]  

  • 12. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
    Blackwell CW; López Castillo H
    J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-acting injection therapies: New opportunities and challenges].
    Lee M
    MMW Fortschr Med; 2024 Jul; 166(Suppl 2):32-34. PubMed ID: 38980615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
    Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
    AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV.
    Mazzitelli M; Agostini E; Vania E; Presa N; Sasset L; Leoni D; Gardin S; Scaglione V; Cattelan A
    HIV Res Clin Pract; 2024 Dec; 25(1):2351258. PubMed ID: 38726811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the significance of the pharmacokinetic profile and potential drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine?
    Bettonte S; Berton M; Marzolini C
    Expert Opin Drug Metab Toxicol; 2023; 19(5):243-247. PubMed ID: 37293864
    [No Abstract]   [Full Text] [Related]  

  • 17. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.
    Sax PE; Thompson MA; Saag MS;
    JAMA; 2024 Mar; 331(12):1060-1061. PubMed ID: 38427337
    [No Abstract]   [Full Text] [Related]  

  • 18. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy.
    Rousseau A; McGrath E; Benjamins L; Cockern S; Meade J; Houston K; Breaux M; Secord E
    J Pediatric Infect Dis Soc; 2024 May; 13(5):285-287. PubMed ID: 38591356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
    Thoueille P; Saldanha SA; Schaller F; Choong E; Veuve F; Munting A; Cavassini M; Braun D; Günthard HF; Duran Ramirez JJ; Surial B; Furrer H; Rauch A; Ustero P; Calmy A; Stöckle M; Di Benedetto C; Bernasconi E; Schmid P; Marzolini C; Girardin FR; Buclin T; Decosterd LA; Guidi M;
    Clin Pharmacol Ther; 2024 Jun; 115(6):1450-1459. PubMed ID: 38519844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.